4.6 Review

News at XI: moving beyond factor Xa inhibitors

期刊

JOURNAL OF THROMBOSIS AND HAEMOSTASIS
卷 21, 期 7, 页码 1692-1702

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtha.2023.04.021

关键词

anticoagulant; coagulation; factor XI; thromboembolism; thrombosis

向作者/读者索取更多资源

Oral anticoagulants are widely used for preventing and treating thrombosis. Direct oral anticoagulants (DOACs) such as dabigatran and apixaban have replaced traditional anticoagulants. New DOACs like asundexian and milvexian, targeting FXIa, offer potential advantages over existing ones.
Oral anticoagulants are a mainstay for the prevention and treatment of arterial and venous thrombosis. Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists for many indications. Currently available DOACs include dabigatran, which inhibits thrombin, and apixaban, edoxaban, and rivaroxaban, which inhibit factor (F) Xa. A new class of DOACs is under development. These new DOACs, which include asundexian and milvexian, inhibit FXIa, which is positioned in the intrinsic pathway of coagulation. Anticoagulants that target FXIa have the potential to be safer than the current DOACs because there is emerging evidence that FXI is essential for thrombosis but mostly dispensable for hemostasis. In addition to the oral inhibitors of FXIa, parenteral inhibitors are also under development. These include fesomersen, an antisense oligonucleotide that reduces the hepatic synthesis of FXI; abelacimab, an antibody that binds to FXI and blocks its activation; and osocimab, an FXIa inhibitory antibody. Focusing on these new agents, this article describes the unmet needs in oral anticoagulation therapy, explains why FXI is a promising target for new oral anticoagulants, reviews phase 2 clinical data on new agents, describes ongoing phase 3 trials, and provides a perspective on the opportunities and challenges for FXI inhibitors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据